Inhibiteur de Janus Kinase-Tofacitinib associé au pemphigus : Analyse des données du système de notification des effets indésirables de la FDA

ExpExpert Opin Drug Saf. 2023;22(12):1317–1320 doi: 10.1080/14740338.2023.2248872

This study presents initial data suggesting an association between the use of JAK inhibitors and pemphigus. This research used the FAERS database to investigate connections between JAK inhibitor usage and the occurrence of pemphigus as an adverse event.

The authors found that females, individuals aged 40–49 and RA patients were more susceptible to pemphigus than other demographics, perhaps due to the immunopathogenesis. Higher rates of pemphigus were also observed in patients receiving tofacitinib compared with upadacitinib.

Keywords:


Publication thumbnail: Inhibiteur de Janus Kinase-Tofacitinib associé au pemphigus : Analyse des données du système de notification des effets indésirables de la FDA
LinkedIn